Search research articles
Contact Us
Filters
Showing results (501-510 of 512) with videos related to
Page
of 52
Sort By:
Lancet (London, England)
|
July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Nature Communications
|
January 22, 2025
Myosin-based nucleation of actin filaments contributes to stereocilia development critical for hearing
Zane G Moreland, Fangfang Jiang, Carlos Aguilar, et al.
Open Forum Infectious Diseases
|
September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
Graham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 20, 2008
Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
Haixia Wang, Zheming Ruan, James J Li, et al.
Journal of Medicinal Chemistry
|
April 9, 2009
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation
Alexandra A Nirschl, Yan Zou, Stanley R Krystek, et al.
Research Square
|
December 4, 2023
Epistasis regulates genetic control of cardiac hypertrophy
Qianru Wang, Tiffany M Tang, Nathan Youlton, et al.
Nature Cardiovascular Research
|
June 5, 2025
Epistasis regulates genetic control of cardiac hypertrophy
Qianru Wang, Tiffany M Tang, Michelle Youlton, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 21, 2023
Epistasis regulates genetic control of cardiac hypertrophy
Qianru Wang, Tiffany M Tang, Nathan Youlton, et al.
Journal of Medicinal Chemistry
|
June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
Kevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Journal of Alzheimer'S Disease : JAD
|
October 16, 2023
Multi-Site Cross-Site Inter-Rater and Test-Retest Reliability and Construct Validity of the MarkVCID White Matter Hyperintensity Growth and Regression Protocol
Ahmed A Bahrani, Erin L Abner, Charles S DeCarli, et al.
Page
of 52
Search research articles
Search
Showing results (501-510 of 512) with videos related to
Sort By:
Page
of 52
Lancet (London, England)
|
July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Nature Communications
|
January 22, 2025
Myosin-based nucleation of actin filaments contributes to stereocilia development critical for hearing
Zane G Moreland, Fangfang Jiang, Carlos Aguilar, et al.
Open Forum Infectious Diseases
|
September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
Graham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 20, 2008
Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
Haixia Wang, Zheming Ruan, James J Li, et al.
Journal of Medicinal Chemistry
|
April 9, 2009
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation
Alexandra A Nirschl, Yan Zou, Stanley R Krystek, et al.
Research Square
|
December 4, 2023
Epistasis regulates genetic control of cardiac hypertrophy
Qianru Wang, Tiffany M Tang, Nathan Youlton, et al.
Nature Cardiovascular Research
|
June 5, 2025
Epistasis regulates genetic control of cardiac hypertrophy
Qianru Wang, Tiffany M Tang, Michelle Youlton, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 21, 2023
Epistasis regulates genetic control of cardiac hypertrophy
Qianru Wang, Tiffany M Tang, Nathan Youlton, et al.
Journal of Medicinal Chemistry
|
June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
Kevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Journal of Alzheimer'S Disease : JAD
|
October 16, 2023
Multi-Site Cross-Site Inter-Rater and Test-Retest Reliability and Construct Validity of the MarkVCID White Matter Hyperintensity Growth and Regression Protocol
Ahmed A Bahrani, Erin L Abner, Charles S DeCarli, et al.
Page
of 52